OR4D6: A Potential Drug Target and Biomarker for Ovarian Cancer
OR4D6: A Potential Drug Target and Biomarker for Ovarian Cancer
Ovarian cancer is a leading cause of cancer death in women, affecting over 21,000 new cases and 15,120 deaths in the United States alone in 2019. Despite advances in treatment, the survival rate for ovarian cancer has remained largely stagnant in recent years. Therefore, identifying new drug targets and biomarkers for the disease is crucial for improving treatment outcomes. OR4D6, a G protein-coupled receptor (GPCR) located on the nuclear envelope of ovarian cancer cells, has been identified as a potential drug target and biomarker for ovarian cancer.
OR4D6 is a GPCR that plays a role in cell signaling, specifically in the regulation of cell adhesion and migration. It is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract, and has been implicated in the development and progression of various diseases, including ovarian cancer. OR4D6 has also been shown to be overexpressed in ovarian cancer tissues, which may contribute to the development and progression of the disease.
Despite the potential implications of OR4D6 as a drug target, much research is needed to fully understand its role in ovarian cancer. Several studies have investigated the effects of drugs that specifically target OR4D6 on the growth and progression of ovarian cancer cells. These studies have shown that inhibiting OR4D6 can inhibit the growth and survival of ovarian cancer cells, suggesting that OR4D6 may be a valuable drug target for the treatment of ovarian cancer.
In addition to its potential as a drug target, OR4D6 has also been investigated as a biomarker for ovarian cancer. Ovarian cancer is often diagnosed through routine Pap smear tests, which can detect abnormal cells in the cervical tissue. However, the accuracy of these tests can be limited, as they may not detect all ovarian cancer cases. Therefore, identifying new biomarkers for ovarian cancer could improve diagnostic accuracy and help to identify patients at risk for the disease.
OR4D6 has been shown to be overexpressed in ovarian cancer tissues, which could be used as a biomarker for the disease. Additionally, studies have shown that OR4D6 is involved in the regulation of cell adhesion and migration, which are important processes in the development and progression of ovarian cancer. Therefore, targeting OR4D6 with drugs that inhibit its activity could potentially lead to the destruction of ovarian cancer cells, which could be used as a biomarker for the disease.
In conclusion, OR4D6 is a GPCR that has been shown to be involved in the regulation of cell adhesion and migration, and is overexpressed in ovarian cancer tissues. Identifying OR4D6 as a potential drug target and biomarker for ovarian cancer could lead to new therapeutic approaches for the treatment of this disease. Further research is needed to fully understand the role of OR4D6 in ovarian cancer and to develop effective treatments.
Protein Name: Olfactory Receptor Family 4 Subfamily D Member 6
Functions: Odorant receptor
More Common Targets
OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4
